Inactive Instrument

Press Releases Orgenesis Inc OTC Bulletin Board

Stocks

US68619K1051

Medical Equipment, Supplies & Distribution

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Mar. 26	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
Mar. 25	Orgenesis Inc. Auditor Raises 'Going Concern' Doubt	CI

Press Releases

Mar. 26	Orgenesis : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
24-11-13	Orgenesis Provides Third Quarter 2024 Business Update	AQ
24-10-21	Orgenesis Commences Trading on OTCQX® Best Market	AQ
24-09-23	Orgenesis Announces Reverse Stock Split	AQ
24-08-29	Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia	AQ
24-08-14	Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally	AQ
24-08-08	Orgenesis Provides Second Quarter 2024 Business Update	AQ
24-05-21	Orgenesis Provides Business Update for the First Quarter of 2024	AQ
24-04-15	Orgenesis Provides Year End Business Update	AQ
24-04-15	Orgenesis : Non-Reliance on Previously Issued Financial Report - Form 8-K	PU
24-04-10	Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	AQ
24-03-18	Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference	AQ
24-03-13	Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes	AQ
24-03-04	Orgenesis Inc. Announces $2.3 Million Private Placement	AQ
24-02-29	Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing	AQ
24-01-31	Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic	AQ
23-11-14	Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM	AQ
23-11-13	Orgenesis Provides Business Update for the Third Quarter of 2023	AQ
23-11-08	Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering	AQ
23-11-02	Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding	AQ
23-10-30	Orgenesis Announces Withdrawal of Proposed Public Offering	AQ
23-10-30	Orgenesis Announces Proposed Underwritten Public Offering	AQ
23-09-21	CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States	AQ
23-09-06	Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support	AQ
23-08-11	Orgenesis Provides Business Update for Second Quarter of 2023	AQ